E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：41
|
作者：
Claudiani, Simone [1 ]
Apperley, Jane F. [1 ]
Gale, Robert Peter [1 ]
Clark, Richard [2 ]
Szydlo, Richard [1 ]
Deplano, Simona [1 ]
Palanicawandar, Renuka [1 ]
Khorashad, Jamshid [1 ]
Foroni, Letizia [1 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;
D O I：
10.3324/haematol.2017.168740
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E297 / E299
页数：3
相关论文
共 50 条
  • [31] c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia
    Lucas, Claire M.
    Harris, Robert J.
    Giannoudis, Athina
    Clark, Richard E.
    HAEMATOLOGICA, 2015, 100 (05)
  • [32] Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis
    Chen, Kangkang
    Ruan, Yingying
    Tian, Kewei
    Xiong, Peisheng
    Xia, Nan
    Li, Jin
    Huang, Wen
    Cao, Feiyan
    Chen, Qifeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
    Polakova, Katerina Machova
    Kulvait, Vojtech
    Benesova, Adela
    Linhartova, Jana
    Klamova, Hana
    Jaruskova, Monika
    de Benedittis, Caterina
    Haferlach, Torsten
    Baccarani, Michele
    Martinelli, Giovanni
    Stopka, Tomas
    Ernst, Thomas
    Hochhaus, Andreas
    Kohlmann, Alexander
    Soverini, Simona
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) : 887 - 899
  • [34] Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a systematic review and meta-analysis
    Zheng, Zhenxiang
    Tang, Hao
    Zhang, Xinxia
    Zheng, Liling
    Yin, Zhao
    Zhou, Jie
    Zhu, Yangmin
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [35] BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis
    Kockerols, Camille
    Valk, Peter J. M.
    Dulucq, Stephanie
    Nicolini, Franck-Emmanuel
    Mahon, Francois-Xavier
    Atallah, Ehab
    Mauro, Michael J.
    Radich, Jerald P.
    Bernardi, Simona
    Russo, Domenico
    Farina, Mirko
    Mori, Silvia
    Gambacorti-Passerini, Carlo
    Civettini, Ivan
    Lu, Liu
    Yeung, David
    Branford, Susan
    Colafigli, Gioia
    Breccia, Massimo
    Hogenbirk, Pauline
    van Rosmalen, Joost
    Cornelissen, Jan J.
    Westerweel, Peter E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1632 - 1635
  • [36] Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript
    Dereme, Julien
    Voruz, Sophie
    Solly, Francoise
    Schoumans, Jacqueline
    Blum, Sabine
    ANNALS OF HEMATOLOGY, 2024, 103 (03) : 1027 - 1029
  • [37] Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib
    Elnair, Radowan
    Galal, Ahmed
    BMC CANCER, 2018, 18
  • [38] Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model
    Carter, Bing Z.
    Mak, Po Yee
    Mu, Hong
    Wang, Xiangmeng
    Tao, Wenjing
    Mak, Duncan H.
    Dettman, Elisha J.
    Cardone, Michael
    Zernovak, Oleg
    Seki, Takahiko
    Andreeff, Michael
    HAEMATOLOGICA, 2020, 105 (05) : 1274 - 1284
  • [39] Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia
    Kee, Kyung-Mi
    Kim, Soo-Hyun
    Yang, Seon-Young
    Shin, Jeong-U
    Nam, Yoon-Won
    Jang, Eun-Jung
    Kim, Hong-Tae
    Lee, Se-Min
    Park, Sung-Ho
    Kim, Dong-Wook
    LEUKEMIA RESEARCH, 2022, 112
  • [40] Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR-ABL1: A report of four cases from India
    Sazawal, Sudha
    Chhikara, Sunita
    Singh, Kanwaljeet
    Chaubey, Rekha
    Mahapatra, Manoranjan
    Seth, Tulika
    Saxena, Renu
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (02) : 107 - +
12345